Armata receives $3.7M additional DoW funding for AP-SA02 Phase 3; total $32.4M

Armata Pharmaceuticals, Inc.

Received $3.7M non-dilutive funding from U.S. Department of War for AP-SA02 Phase 3 development.
Cumulative DoW funding under award now $32.4M, adding to $28.7M previously provided.
Funding supports adjunctive treatment for complicated S. aureus bacteremia (MSSA/MRSA).

item 8.01 item 9.01

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-109809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.